Quick Answer
LB PHARMACEUTICALS INC reported Cash and Equivalents of $250.17 million for fiscal year 2025.
LB PHARMACEUTICALS INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $250.17M | +988.8% |
| 2024 | $22.98M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $269.74M | — | +1073.9% |
| December 31, 2024 | $22.98M | — | — |
- LB PHARMACEUTICALS INC showed an increase of +988.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2024–2025 period, LB PHARMACEUTICALS INC’s cash and equivalents has grown by 988.8% (from $22.98 million to $250.17 million).
- The most recent figure is from LB PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: